BACKGROUND Appalachia is a geographic region with high cervical cancer incidence and mortality rates, yet little is known about human papillomavirus (HPV) vaccination in this region. We determined HPV vaccine coverage among adolescent females from Appalachia, made comparisons to non-Appalachian females, and examined how coverage differs across subregions within Appalachia. METHODS We analyzed...

Routine immunization is recommended for adolescents aged 11-12 years by the Advisory Committee on Immunization Practices (ACIP) for protection against diseases including pertussis, meningococcal disease, and human papillomavirus (HPV)-associated cancers. To assess vaccination coverage among adolescents, CDC analyzed data collected regarding 20,827 adolescents through the 2014 National Immunizat...

BACKGROUND From 2005 through 2007, 3 vaccines were added to the adolescent vaccination schedule: tetanus-diphtheria-acellular pertussis (TdaP); meningococcal conjugate (MenACWY); and human papillomavirus (HPV) for girls. OBJECTIVE To assess implementation of new adolescent vaccination recommendations. METHODS Data from the 2006-2009 National Immunization Survey-Teen, an annual provider-veri...

Our aim was to examine the potential incremental impact of vaccinating boys against human papillomavirus (HPV) on vaccine-type infection in females and males, using an individual-based HPV transmission-dynamic model. Under base assumptions (vaccine efficacy = 99%, duration of protection = 20 years, coverage = 70%), vaccinating 12-year-old boys, in addition to girls, resulted in an incremental r...

Human papillomavirus (HPV) 16 and 18 are found to be involved in 80% of anal cancers. Two vaccines against HPV infections are currently available, and vaccination policies aim to decrease mainly, incidence of cervical cancers. Moreover, an impact of HPV vaccination on the incidence of anal cancer can also be expected. Our aim was to assess the potential benefits of HPV vaccination on the occurr...

PURPOSE Potential barriers to widespread vaccination of adolescent girls against human papillomavirus (HPV) infection are poorly understood. We provide an overview of potential barriers to provision of HPV vaccine and empirical data on the concerns of medical practices that may inhibit HPV vaccine provision. METHOD We conducted phone interviews with medical practices in rural areas in southea...

BACKGROUND HPV vaccine coverage is far from ideal in Valencia, Spain, and this could be partially related to the low knowledge about the disease and the vaccine, therefore we assessed these, as well as the attitude towards vaccination in adolescent girls, and tried to identify independently associated factors that could potentially be modified by an intervention in order to increase vaccine cov...

OBJECTIVE To describe quadrivalent human papillomavirus (HPV) vaccination coverage achieved in the HPV vaccination catch-up program for girls aged 12-17 years. DESIGN Analysis of data from the Australian National HPV Vaccination Program Register. PARTICIPANTS Girls aged 12-17 years as at 30 June 2007. MAIN OUTCOME MEASURES HPV vaccine coverage by dose (1, 2 and 3), age and state of reside...

Since the introduction of HPV vaccination programs in Canada in 2007, coverage has been below public health goals in many provinces and territories. This analysis investigated the determinants of HPV non-vaccination and vaccine refusal. Data from the Childhood National Immunization Coverage Survey (CNICS) 2013 were used to estimate the prevalence of HPV non-vaccination and parental vaccine refu...

BACKGROUND Human papillomavirus (HPV) vaccines are ideally administered before HPV exposure; therefore, catch-up programs for girls past adolescence have not been readily funded. We evaluated the benefits and cost-effectiveness of a delayed, 1-year female catch-up vaccination program in Norway. METHODS We calibrated a dynamic HPV transmission model to Norwegian data and projected the costs an...